P53/MDM2 Complex-Based Targeted Strategies in Colon Adenocarcinoma

Authors

  • Athanasios Niotis Second Department of Propedeutic Surgery, ‘Laiko’ General Hospital, Medical School, National and Kapodistrian University, Athens
  • Evangelos Tsiambas Department of Cytology, 417 Veterans Army Hospital (NIMTS), Athens; Department of Pathology, Medical School, National and Kapodistrian University, Athens
  • Dimitrios Dimitroulis Second Department of Propedeutic Surgery, ‘Laiko’ General Hospital, Medical School, National and Kapodistrian University, Athens
  • Helen Sarlanis 3 Department of Pathology, Medical School, National and Kapodistrian University, Athens
  • Evangelos Falidas Department of Surgery, Halkida General Hospital, Halkida
  • Nikolaos Kavantzas Department of Pathology, Medical School, National and Kapodistrian University, Athens
  • Constantinos A. Constantinides Department of Urology, Medical School, National and Kapodistrian University, Athens

DOI:

https://doi.org/10.5644/ama2006-124.398

Keywords:

Colon, Carcinoma, p53-MDM2, Immunohistochemistry, Genetics

Abstract

In the current molecular review, we describe the mechanisms of TP53/MDM2 deregulation and their impact on the colon adenocarcinoma molecular substrate and phenotype. Among the genes that are critically altered in carcinogenesis, the TP53 tumor suppressor gene is of major importance. The TP53 gene (gene locus: 17p13.1) regulates the cell cycle by controlling the G1/S and G2/M checkpoints securing the normal sequence of cell cycle phases. Furthermore, it is involved in apoptosis programmed cell death. The gene is mutated or epigenetically altered in all epithelial malignancies, including colon adenocarcinoma. Additionally, Mouse Double Minute 2 Homolog (MDM2), a proto-oncogene (12q14.3), acts as a major negative regulator for p53 expression in the p53-MDM2 auto-regulatory pathway. MDM2 binds directly to p53 and represses its transcriptional activity, promoting p53 degradation.

Conclusion. In colon adenocarcinoma, MDM2 oncogene overexpression directly influences p53 oncoprotein expression levels.

Downloads

Download data is not yet available.

Downloads

Published

2023-06-11

How to Cite

Niotis, A. ., Tsiambas, E. ., Dimitroulis, D. ., Sarlanis, H. ., Falidas, E. ., Kavantzas, N. ., & Constantinides, C. A. . (2023). P53/MDM2 Complex-Based Targeted Strategies in Colon Adenocarcinoma. Acta Medica Academica, 52(1), 24–29. https://doi.org/10.5644/ama2006-124.398

Issue

Section

Clinical Medicine

Similar Articles

<< < 1 2 3 4 

You may also start an advanced similarity search for this article.